Plain-English translation of NCT05877599 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new treatment called , which is a type of immune therapy designed to fight certain advanced cancers. The study focuses on cancers that have a specific genetic change (called TP53 R175H mutation) and patients who have a matching immune marker (HLA-A*02:01). Researchers will first test different doses of the medication to find the safest and most effective level, then expand the study to learn more about how well it works in different cancer types.
Some advanced cancers have a specific genetic mutation that may make them vulnerable to a targeted immune attack. This study exists to see whether this medication can safely teach the body's immune cells to recognize and fight these cancers, offering hope to patients who have run out of standard treatment options.
You likely qualify if…
You likely don't qualify if…
You would receive infusions of the medication at a clinic or hospital, with the exact schedule depending on which dose group you join. The study involves multiple visits for blood tests, imaging scans, and health assessments to monitor how you respond and watch for side effects. The first part of the study focuses on finding the right dose, while later parts will look more closely at how well the treatment works for specific cancer types.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States